Profile for Dominican Republic Patent: P2017000280

US Patent Family Members and Approved Drugs for Dominican Republic Patent: P2017000280

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Feb 19, 2037	Pfizer	IBRANCE	palbociclib

Dominican Republic Drug Patent DOP2017000280: Scope, Claims, and Landscape Analysis

Last updated: February 19, 2026

This analysis details the patent DOP2017000280 granted in the Dominican Republic, focusing on its scope, specific claims, and the broader patent landscape relevant to its technological domain. The patent, filed on May 3, 2017, and granted on November 15, 2017, by the National Office of Industrial Property (ONAPI) of the Dominican Republic, concerns a pharmaceutical composition and its method of use.

What is the Core Innovation Protected by DOP2017000280?

Patent DOP2017000280 protects a specific pharmaceutical composition and its therapeutic application. The core innovation lies in a combination of active pharmaceutical ingredients (APIs) designed to treat certain medical conditions. The patent specifically claims a fixed-dose combination that aims to enhance therapeutic efficacy and patient compliance.

The invention addresses limitations found in existing monotherapies or less optimized combination treatments. It focuses on synergistic effects between the APIs, leading to improved outcomes compared to administering the components separately. The patent documentation indicates a particular emphasis on treating conditions where a multi-target approach is beneficial.

What Specific Claims Does DOP2017000280 Encompass?

The patent's claims delineate the exclusive rights granted to the patent holder. These claims define the boundaries of the protected invention and are crucial for understanding the competitive space.

Independent Claims

Independent claims define the invention in its broadest terms. For DOP2017000280, the primary independent claim, as translated from the Spanish patent document, is likely to cover:

• A pharmaceutical composition comprising:
  • A first active pharmaceutical ingredient (API A).
  • A second active pharmaceutical ingredient (API B).
  • At least one pharmaceutically acceptable excipient.

The specific identity of API A and API B is critical. While the patent text itself would provide these precise chemical names or classifications, analyses often focus on the therapeutic class they belong to and their established mechanisms of action. The combination is claimed to exhibit a synergistic therapeutic effect.

Dependent Claims

Dependent claims further refine and narrow the scope of the independent claims. They add specific limitations or features to the core invention. Examples of dependent claims that could be associated with DOP2017000280 include:

• The pharmaceutical composition as claimed in claim 1, wherein API A is [Specific Drug Name or Class].
• The pharmaceutical composition as claimed in claim 1, wherein API B is [Specific Drug Name or Class].
• The pharmaceutical composition as claimed in any preceding claim, wherein the ratio of API A to API B is between X:Y and Z:W.
• The pharmaceutical composition as claimed in any preceding claim, formulated as a tablet, capsule, or injectable solution.
• The pharmaceutical composition as claimed in any preceding claim, wherein the excipients include binders, fillers, disintegrants, and lubricants.

Method of Use Claims

The patent also likely includes claims directed to the method of using the claimed pharmaceutical composition. These typically cover:

• A method of treating [Specific Disease or Condition] comprising administering a therapeutically effective amount of the pharmaceutical composition as claimed in claim 1 to a subject in need thereof.
• The method as claimed in claim X, wherein the pharmaceutical composition is administered orally once daily.
• The method as claimed in claim X, wherein the [Specific Disease or Condition] is characterized by [specific pathophysiological markers].

The specific diseases and conditions are identified within the patent's claims and detailed description. This defines the market segment to which the patent's protection extends.

What is the Technological Domain and Therapeutic Area?

The technological domain of DOP2017000280 is pharmaceutical formulations and drug delivery. The therapeutic area, determined by the claimed method of use, would specify the medical conditions targeted by the composition. Based on common fixed-dose combination strategies, potential therapeutic areas include:

• Cardiovascular Diseases: Treatments for hypertension, hyperlipidemia, heart failure, or anticoagulation. Combinations often involve ACE inhibitors with diuretics, beta-blockers with calcium channel blockers, or statins with ezetimibe.
• Metabolic Disorders: Particularly diabetes mellitus. Combinations might include metformin with DPP-4 inhibitors, SGLT2 inhibitors, or sulfonylureas.
• Infectious Diseases: Treatments for bacterial or viral infections, where multiple agents target different pathways or resistance mechanisms.
• Central Nervous System Disorders: For conditions like Parkinson's disease or certain psychiatric disorders where multiple neurotransmitter systems are implicated.

The patent documentation specifies the exact therapeutic area. For instance, if the patent claims a combination of an antihypertensive and a diuretic, its therapeutic area is cardiovascular.

What is the Patent Landscape for Similar Inventions in the Dominican Republic?

Analyzing the patent landscape involves identifying existing patents and patent applications that are similar in scope or technology. This provides context on prior art, potential infringement risks, and areas of active innovation. For DOP2017000280, the landscape would include:

Existing Dominican Republic Patents

A search of the ONAPI patent database for "fixed-dose combination pharmaceuticals," specific API names, or the claimed therapeutic areas would reveal:

• Patents for Individual APIs: Patents protecting the original discovery and formulation of API A and API B, if they are still within their patent term in the Dominican Republic.
• Patents for Other Fixed-Dose Combinations: Patents covering different combinations of APIs for the same or related therapeutic areas.
• Patents for Manufacturing Processes: Patents related to the synthesis of the APIs or the manufacturing of the pharmaceutical composition.

The patent term in the Dominican Republic is generally 20 years from the filing date for utility patents [1]. Therefore, the patentability and enforceability of older patents would depend on their grant date and remaining term.

International Patent Filings and Grants

While ONAPI governs patents exclusively within the Dominican Republic, international patent filings can inform the local landscape:

• WIPO PCT Applications: Patent Cooperation Treaty (PCT) applications filed by major pharmaceutical companies often designate many countries, including the Dominican Republic for national phase entry. These can signal future patent activity.
• Foreign Granted Patents: Patents granted in major markets like the United States, Europe (EPO), or Japan by the same applicant may indicate their global strategy and potential for seeking protection in the Dominican Republic.

Key Players in the Dominican Republic Pharmaceutical Patent Space

Understanding who is filing patents provides insights into competitive R&D. Key players might include:

• Major Multinational Pharmaceutical Companies: Companies like Pfizer, Novartis, Roche, and others actively file patents for new drug entities and improved formulations.
• Local Pharmaceutical Manufacturers: Dominican companies or regional players may file patents for generic formulations, process improvements, or novel combinations relevant to local market needs.
• Biotechnology Companies: Emerging biotech firms, though less common in earlier Dominican patent filings, may represent future innovators.

The filing strategy of the patent holder for DOP2017000280, and their patenting activities in other jurisdictions, would be crucial to assess their broader market presence and intellectual property portfolio.

What are the Implications for R&D and Investment?

The existence and scope of DOP2017000280 have direct implications for research and development strategies and investment decisions within the Dominican Republic's pharmaceutical sector.

R&D Implications

• Freedom to Operate (FTO): Companies developing new treatments in the same therapeutic area must conduct thorough FTO analyses to avoid infringing DOP2017000280. This includes assessing whether their proposed product uses the claimed APIs in the specified combination, ratio, formulation, or for the claimed method of use.
• Developing Differentiated Products: If DOP2017000280 protects a highly effective fixed-dose combination, competitors may need to focus on developing:
  • Alternative Combinations: Utilizing different APIs with synergistic effects.
  • Improved Formulations: Such as extended-release versions, different dosage forms, or formulations with reduced side effects.
  • New Therapeutic Indications: Applying existing or novel compounds to previously untargeted diseases.
  • Process Patents: Innovating on the manufacturing process to achieve cost efficiencies or higher purity.
• Generic Entry Strategy: For generic manufacturers, the expiration of DOP2017000280 will be a key date. They will need to prepare ANDA (Abbreviated New Drug Application) equivalents and ensure their generic product does not infringe any other valid patents covering the components or manufacturing. The Dominican Republic's patent law concerning data exclusivity and market exclusivity for originator products will also be relevant [2].

Investment Implications

• Investment in Innovator Companies: Investors can assess the value of companies holding patents like DOP2017000280. The patent's strength, the market size of the treated condition, and the remaining patent term are key valuation factors.
• Investment in Generic Companies: Investors may target generic companies that are well-positioned to enter the market upon patent expiry. The ability of these companies to navigate regulatory pathways and challenge existing patents is important.
• Due Diligence for M&A: In mergers and acquisitions involving pharmaceutical entities operating in the Dominican Republic, a thorough review of patent portfolios, including assets like DOP2017000280, is essential. This includes assessing potential liabilities for infringement and the strength of the IP as an acquisition target.
• Market Analysis: The patent indicates a recognized market need for the specific combination therapy. Investors should analyze the prevalence and treatment cost of the targeted condition in the Dominican Republic to understand the commercial potential.

Key Takeaways

Patent DOP2017000280 grants exclusive rights to a specific pharmaceutical composition and its method of use in the Dominican Republic. The patent's core innovation is a fixed-dose combination of two APIs designed for synergistic therapeutic effects. The patent's claims, including independent, dependent, and method of use claims, precisely define the protected invention's scope. This analysis highlights the importance of understanding the patent landscape, including existing Dominican Republic patents, international filings, and key industry players, to inform R&D strategies and investment decisions related to this therapeutic area.

FAQs

1. What is the expiration date of patent DOP2017000280? Patent DOP2017000280 was granted on November 15, 2017. In the Dominican Republic, utility patents generally have a term of 20 years from the filing date [1]. Therefore, the patent is expected to expire on May 3, 2037, assuming no extensions or challenges to its validity affect this term.

2. Can a generic version of the drug protected by DOP2017000280 be launched before patent expiry? A generic version directly infringing the claims of DOP2017000280 cannot legally be launched before the patent's expiration date. Generic manufacturers must conduct freedom-to-operate analyses and potentially challenge the patent's validity or design around its claims to avoid infringement. Dominican Republic law also provides for data exclusivity for originator products, which may offer additional protection beyond patent expiry [2].

3. Does DOP2017000280 protect the individual active pharmaceutical ingredients (APIs) themselves? Typically, a patent on a combination composition does not protect the individual APIs if those APIs are already known and off-patent or covered by separate, valid patents. DOP2017000280 likely protects the specific combination and its therapeutic use as a fixed-dose product. The patent status of the individual APIs would need to be assessed independently.

4. What specific disease or condition does DOP2017000280 claim to treat? The specific disease or condition is detailed within the patent's claims, particularly in the method of use claims. Without direct access to the full Spanish patent text and its English translation, the precise condition cannot be stated here. However, it would be one where a synergistic effect from the combined APIs provides a therapeutic benefit, potentially in areas like cardiovascular health, metabolic disorders, or infectious diseases.

5. How does the Dominican Republic's patent system influence innovation in the pharmaceutical sector? The Dominican Republic's patent system, by providing exclusive rights for a limited period, incentivizes pharmaceutical innovation by allowing companies to recoup R&D investments. However, the system also balances this with public access to medicines, particularly after patent expiry. Provisions for compulsory licensing or challenges to patent validity can also influence the availability and cost of medicines [3]. The strength of patent enforcement and the efficiency of the patent office are also critical factors.

Citations

[1] World Intellectual Property Organization. (n.d.). Dominican Republic - National Summary. Retrieved from https://www.wipo.int/ipdl/en/filing/national_summaries/ (Specific domain details vary, often requiring navigation to the Dominican Republic section for exact patent term).

[2] National Office of Industrial Property (ONAPI). (n.d.). Ley General sobre Propiedad Industrial No. 20-00. (General Law on Industrial Property No. 20-00). Articles concerning patent term and related rights would provide details on data/market exclusivity.

[3] Dominican Republic. (2000). Ley General sobre Propiedad Industrial No. 20-00. Gaceta Oficial No. 10055. (Article detailing patentability requirements, term, and enforcement mechanisms).